...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.
【24h】

Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.

机译:同源癌胚细胞粘附分子1相互作用抑制人肿瘤浸润淋巴细胞的效应器功能。

获取原文
获取原文并翻译 | 示例

摘要

Efficient antitumor immune response requires the coordinated function of integrated immune components, but is finally exerted by the differentiated effector tumor-infiltrating lymphocytes (TIL). TIL cells comprise, therefore, an exciting platform for adoptive cell transfer (ACT) in cancer. In this study, we show that the inhibitory carcinoembryonic Ag cell adhesion molecule 1 (CEACAM1) protein is found on virtually all human TIL cells following preparation protocols of ACT treatment for melanoma. We further demonstrate that the CEACAM1 homophilic interactions inhibit the TIL effector functions, such as specific killing and IFN-gamma release. These results suggest that CEACAM1 may impair in vivo the antitumor response of the differentiated TIL. Importantly, CEACAM1 is commonly expressed by melanoma and its presence is associated with poor prognosis. Remarkably, the prolonged coincubation of reactive TIL cells with their melanoma targets results in increased functional CEACAM1 expression by the survivingtumor cells. This mechanism might be used by melanoma cells in vivo to evade ongoing destruction by tumor-reactive lymphocytes. Finally, CEACAM1-mediated inhibition may hinder in many cases the efficacy of TIL ACT treatment of melanoma. We show that the intensity of CEACAM1 expression on TIL cells constantly increases during ex vivo expansion. The implications of CEACAM1-mediated inhibition of TIL cells on the optimization of current ACT protocols and on the development of future immunotherapeutic modalities are discussed.
机译:有效的抗肿瘤免疫反应需要整合的免疫成分的协调功能,但最终会由分化的效应肿瘤浸润淋巴细胞(TIL)发挥作用。因此,TIL细胞包括一个令人兴奋的平台,可用于癌症中的过继细胞转移(ACT)。在这项研究中,我们表明,按照ACT治疗黑素瘤的制备方案,实际上在所有人类TIL细胞上都发现了抑制癌胚Ag细胞粘附分子1(CEACAM1)蛋白。我们进一步证明,CEACAM1同源相互作用抑制TIL效应子功能,例如特异性杀伤和IFN-γ释放。这些结果表明CEACAM1可能在体内损害分化的TIL的抗肿瘤反应。重要的是,CEACAM1通常由黑色素瘤表达,其存在与不良预后有关。值得注意的是,反应性TIL细胞与其黑色素瘤靶标的长时间共孵育会导致存活的肿瘤细胞功能性CEACAM1表达增加。黑色素瘤细胞可在体内使用这种机制来逃避肿瘤反应性淋巴细胞的持续破坏。最后,在许多情况下,CEACAM1介导的抑制作用可能会阻碍TIL ACT治疗黑色素瘤的疗效。我们显示在体外扩增过程中,TIL细胞上CEACAM1表达的强度不断增加。讨论了CEACAM1介导的TIL细胞抑制对当前ACT方案的优化和未来免疫治疗方法发展的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号